GlassScriptPhysician profile
Norman Taylor
NPI 1811937469
$16,101.50
in general payments reported to CMS, 2019-2025
55 companies · $1,835 in 2025
The $1,835 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,777 · 2020: $2,421 · 2021: $2,074 · 2022: $2,282 · 2023: $2,479 · 2024: $2,232 · 2025: $1,835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,546.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,877.29 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,391.46 | 2019-2025 | Farxiga, Breztri, Wainua |
| Janssen Pharmaceuticals, INC | $1,218.48 | 2019-2024 | Xarelto |
| Pfizer INC. | $1,215.89 | 2019-2025 | |
| Dexcom, INC. | $944.47 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Sanofi-Aventis U.S. LLC | $904.70 | 2019-2023 | |
| Alnylam Pharmaceuticals INC. | $734.38 | 2022-2025 | Amvuttra |
| Arbor Pharmaceuticals, INC. | $719.14 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $691.36 | 2021-2025 | |
| Lilly USA, LLC | $643.95 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $567.35 | 2019-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $563.18 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $481.92 | 2019-2021 | |
| Amgen INC. | $426.17 | 2019-2025 | Uplizna, Evenity, Prolia |
| Abbott Laboratories | $398.96 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.